Area of research
Psychiatry and Mental health · Physiology
Research interest
Research interests include Dementia and Cognitive Impairment Research, Alzheimer's disease research and treatments, Medical Imaging Techniques and Applications, and Functional Brain Connectivity Studies.
White Matter Abnormalities and Cognition in Aging and Alzheimer Disease
Concordance Between Amyloid-PET Quantification and Real-World Visual Reads
Integrative multiomics reveals common endotypes across PSEN1, PSEN2, and APP mutations in familial Alzheimer’s disease
Relationships of PGRN with sTREM2 in AD continuum and non-AD pathophysiology and their reciprocal roles in modulating amyloid pathology: two population-based study
Individuals with Alzheimer's disease and low tau burden: Characteristics and implications
Multiomics analysis to explore blood metabolite biomarkers in an Alzheimer’s Disease Neuroimaging Initiative cohort
A novel spatiotemporal graph convolutional network framework for functional connectivity biomarkers identification of Alzheimer’s disease
Advanced Mycelium Skins for Sustainable Electronics
The POINTER Imaging baseline cohort: Associations between multimodal neuroimaging biomarkers, cardiovascular health, and cognition
Etiology of White Matter Hyperintensities in Autosomal Dominant and Sporadic Alzheimer Disease
Amyloid and tau‐PET in early‐onset AD: Baseline data from the Longitudinal Early‐onset Alzheimer's Disease Study (LEADS)
Deep learning-based polygenic risk analysis for Alzheimer’s disease prediction
Positron emission tomography and magnetic resonance imaging methods and datasets within the Dominantly Inherited Alzheimer Network (DIAN)
Prevalence and Clinical Implications of a β-Amyloid–Negative, Tau-Positive Cerebrospinal Fluid Biomarker Profile in Alzheimer Disease
The Sporadic Early‐onset Alzheimer's Disease Signature Of Atrophy: Preliminary Findings From The Longitudinal Early‐onset Alzheimer's Disease Study (LEADS) Cohort
Sex and <i>APOE ε4</i> carrier effects on atrophy, amyloid PET, and tau PET burden in early‐onset Alzheimer's disease
Pathogenic variants in the Longitudinal Early‐onset Alzheimer's Disease Study cohort
Longitudinal head-to-head comparison of 11C-PiB and 18F-florbetapir PET in a Phase 2/3 clinical trial of anti-amyloid-β monoclonal antibodies in dominantly inherited Alzheimer’s disease
Profiling baseline performance on the Longitudinal Early‐Onset Alzheimer's Disease Study (LEADS) cohort near the midpoint of data collection
Cerebrospinal fluid biomarkers in the Longitudinal Early‐onset Alzheimer's Disease Study
Characterizing Heterogeneity in Neuroimaging, Cognition, Clinical Symptoms, and Genetics Among Patients With Late-Life Depression
Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer’s disease
An IL1RL1 genetic variant lowers soluble ST2 levels and the risk effects of APOE-ε4 in female patients with Alzheimer’s disease
Dissociation of tau pathology and neuronal hypometabolism within the ATN framework of Alzheimer’s disease
Quantification of amyloid beta and tau PET without a structural MRI
MycelioTronics: Fungal mycelium skin for sustainable electronics.
The Polygenic Risk Score Knowledge Base offers a centralized online repository for calculating and contextualizing polygenic risk scores
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease
Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease